Skip to main content
Clinical Trials/NCT01864317
NCT01864317
Terminated
Phase 2

Assessment of Optic Nerve Radiation in Patients With Glaucoma and Ocular Hypertension by 7 Tesla Diffusion Tensor Imaging

Medical University of Vienna1 site in 1 country120 target enrollmentNovember 2015

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Primary Open Angle Glaucoma
Sponsor
Medical University of Vienna
Enrollment
120
Locations
1
Primary Endpoint
High resolution functional and structural imaging of the visual pathway
Status
Terminated
Last Updated
6 years ago

Overview

Brief Summary

Glaucoma is among the leading causes for blindness in the western world. Elevated intraocular pressure (IOP) has been identified as the most important risk factor. However, some patients progress despite adequate IOP lowering while some subjects with elevated IOP never develop glaucoma. Other patients develop glaucoma although IOP measurements were always in the normal range. Therefore, other factors must be involved. In the last years, studies using MRI have been performed and evidence has accumulated that also changes in retrobulbar structures are present, in particular in the lateral geniculate nucleus and the visual cortex. However, these studies were limited by the low spatial resolution of the MRI instruments used.

The investigators propose to overcome this problem by using an ultrahigh-field Magnetom 7T whole-body MR scanner (Siemens Medical, Germany) installed at the MR Centre of Excellence at the Medical University of Vienna. This scanner is equipped with a 32-channel head coil and the SC72 high-performance gradient system and is thus perfectly suited for structural and functional imaging. The aim of the present study is to investigate whether structural and functional parameters are altered in patients with primary open angle glaucoma (POAG), normal tension glaucoma (NTG), ocular hypertension (OHT) compared to healthy control subjects. The exact topographical survey of intracranial structures such as the LGN and the assessment of neuronal structures by DTI may allow for the better assessment of therapeutic responses to new neuroprotective agents.

Registry
clinicaltrials.gov
Start Date
November 2015
End Date
December 2015
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Gerhard Garhofer

Assoc. Prof. PD Dr.

Medical University of Vienna

Eligibility Criteria

Inclusion Criteria

  • Healthy controls
  • Men and women aged over 18 years
  • Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant
  • Normal ophthalmic findings
  • Patients with ocular hypertension
  • Men and women aged over 18 years
  • Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant
  • Normal ophthalmic findings except presence of ocular hypertension (defined as untreated IOP ≥ 21 mmHg on at least three measurements in the medical history, no signs of glaucomatous damage in the optic disc or the glaucoma hemifield test)
  • Patients with primary open angle glaucoma
  • Men and women aged over 18 years

Exclusion Criteria

  • Symptoms of a clinically relevant illness in the 3 weeks before the first study day
  • Presence or history of a severe medical condition as judged by the clinical investigator
  • Abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study
  • Exfoliation glaucoma, pigmentary glaucoma, history of acute angle closure
  • Intraocular surgery within the last 6 months
  • Ocular inflammation or infection within the last 3 months
  • Pregnancy, planned pregnancy or lactating
  • Any metallic, electric, electronic or magnetic device or object not removable except dental fillings
  • Claustrophobia

Outcomes

Primary Outcomes

High resolution functional and structural imaging of the visual pathway

Time Frame: once on the study day (approximately 1 hour)

The visual pathway will be imaged with 7-Tesla MRI. The images will be compared between the study groups.

Secondary Outcomes

  • Intraocular Pressure(once on the study day (1 minute))
  • Visual field test(once on the study day (approximately 20 minutes))
  • Retinal nerve fiber thickness(once on the study day (approximately 10 minutes))

Study Sites (1)

Loading locations...

Similar Trials